Futibatinib (TAS-120)

(Lytgobi®)

Futibatinib (TAS-120)

Drug updated on 1/4/2024

Dosage FormTablets (oral; 4 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.

Product Monograph / Prescribing Information

Document TitleYearSource
Lytgobi (futibatinib) Prescribing Information.2022Taiho Oncology, Inc., Princeton, NJ

Randomized Controlled Trials

Document TitleSex DistributionYearSource
Evaluation of the Mass Balance and Metabolic Profile of Futibatinib in Healthy Participants.
6Subjects
F: 0%
M: 100%
2023Clinical Pharmacology in Drug Development

Sex Distribution:

F:0%
M:100%
6Subjects

Year:

2023

Source:Clinical Pharmacology in Drug Development